Navigation Links
Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
Date:1/11/2011

PALO ALTO, Calif., Jan. 11, 2011 /PRNewswire/ -- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, today announced that the company received U.S. Food and Drug Administration 510(k) clearance for its Acta™ Vessel Occlusion System (VOS).  The Acta VOS provides physicians with a minimally-invasive alternative to current treatment options for an array of common and potentially serious vascular lesions.

The Acta VOS is designed to occlude (close) targeted veins and arteries with great precision. Vascular occlusion is often used to block blood flow to malformed, weakened or leaking vessels, or to benign or malignant tumors.

"The Acta VOS and the Nfocus technology platform on which it's based address an important and, to this date, insufficiently resolved medical need," said Eric Milledge, chairman and CEO, Nfocus Neuromedical.  "The Acta 510(k) clearance is a tangible demonstration of our company's progress and is the first step toward clearance of the Nfocus platform of braided occluders, which includes the Luna™, our flagship product for treating brain aneurysms."

Vascular occlusions were historically accomplished by surgically closing the targeted blood vessel – a traumatic and expensive procedure. More recently, surgeons began placing small wire coils and other vascular plugs through catheters to stop blood from flowing to the area of concern. However, several coils may be required to occlude a single vessel, and occlusions frequently re-open. Pre-clinical studies demonstrate that the Acta VOS stops blood flow in a vessel more quickly and durably than both coils and a predicate plug device.

The Acta VOS uses a self-expandable, multi-layer oval implant made from Nitinol, a nickel-titanium alloy. Nitinol's properties allow the device to easily compress within a conventional catheter, and then rapidly open to full size once deployed within a vessel.  The Acta VOS is mounted on an elegant delivery system that allows physicians to easily retract and reposition the device.  Once the device is deployed and the desired location is achieved, a single lever detaches the Acta VOS, leaving it behind to occlude blood flow.  

"The FDA has rigorous requirements for embolization devices such as the Acta VOS," said Robert O'Holla, vice president of regulatory affairs, Nfocus Neuromedical.  "This 510(k) clearance provides strong validation for both our technology platform and development approach."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms. The company's innovative LUNA™ product is a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils. Nfocus is backed by three major U.S. and OUS-based venture funds: DFJ ePlanet Capital, Technology Partners, and InCube Ventures. Other investors include Raffles Capital and Endeavor Vision. More information can be found at www.nfocusneuro.com.  


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Announces Participation in Arab Health 2011
2. CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business
3. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
4. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
5. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
6. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
7. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
8. Nalco Announces Price Increase
9. Vasomedical Announces Launch of Its Online Company Store
10. Mindray Medical Announces Preliminary 2010 Operating Results
11. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... FRANCISCO , January 24, 2017 ... a value of USD 3.8 billion by 2025, according ... The market growth can be attributed to the rising ... about early diagnosis of micro calcifications in breast tissue. ... Foundation, CDC, and Breast Cancer Organization are promoting the ...
(Date:1/24/2017)... Stock-Callers.com today has issued research reports on four ... Mallinckrodt PLC (NYSE: MNK ), Akorn Inc. (NASDAQ: ... DPLO ). According to pharmaceutical manufacturer PCI Synthesis, there ... Generic Drugs industry, including a possible reduction in FDA red ... a speedier FDA approval process that could reduce its backlog ...
(Date:1/24/2017)... 2017 Optoelectronic components have the capability ... interaction of these components with light makes them ... of applications. These components are primarily used in ... healthcare among others. Growing application across ... power consumption, reliability, scalability, and performance is fueling ...
Breaking Medicine Technology:
(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... ... Novel of Miracles”: a beautiful and poignant glimpse into the unexpected consequences of a ... Would Have Dreamed: A Novel of Miracles” is the creation of published author, Sharon Lee ... shares that she started her spiritual journey later in life, but mentions, “I have had ...
(Date:1/24/2017)... ... 2017 , ... “The Octagon of Spiritual Balances”: a guide for the ... creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, ... religious education and a master degree in theology. , ““The Octagon of Spiritual Balances” ...
(Date:1/24/2017)... Raton, FL (PRWEB) , ... January 23, 2017 ... ... unique, highly refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee ... nutritional products. , CLICK® Coffee Protein Drink Mix has become popular among health-conscious ...
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation ... of the Mexico City Policy, also known as the Global Gag Rule, last ... action, prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family ...
Breaking Medicine News(10 mins):